GSK stops Phase-II lupus trial

Share this article:

The 2012 Galapagos-GlaxoSmithKline alliance has been partly idled. Belgium-based Galapagos announced Monday that GSK has stopped Phase-II exploration of its JAK1 inhibitor GSK2586184 for systemic lupus erythematosus due to lack of effect.

Galapagos said that GSK has put an exploratory half-phase test of this same inhibitor in ulcerative colitis on hold.

Phase-II dosing in a third scenario—psoriasis—has wrapped and the company expects to provide top-line results in the first half of this year. This endpoint means GSK may cough up a milestone payment if results equal proof-of-concept.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.